<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00151957</url>
  </required_header>
  <id_info>
    <org_study_id>SPD485-303</org_study_id>
    <nct_id>NCT00151957</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD and Previously Participated in MTS Trials</brief_title>
  <official_title>A Phase III, Multi-center, Open-label Study of Methylphenidate Transdermal System (MTS) in Pediatric Patients Aged 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Noven Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Noven Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Noven Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the long-term safety of MTS in the symptomatic treatment of children
      aged 6-12 diagnosed with ADHD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Attention-Deficit/Hyperactivity Disorder (ADHD) is a psychiatric disorder characterized by 3
      main symptoms: inattention, hyperactivity and impulsivity. This study will evaluate the
      long-term safety of SPD485 in the symptomatic treatment of children aged 6-12 diagnosed with
      ADHD
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment emergent adverse events over 12 months.</measure>
    <time_frame>Weekly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ADHD-RS-IV scores</measure>
    <time_frame>Weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parent Global Assessment</measure>
    <time_frame>Weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions Scale</measure>
    <time_frame>Weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child's Sleep Habits Questionnaire</measure>
    <time_frame>Weekly</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">450</enrollment>
  <condition>Attention Deficit Disorder With Hyperactivity</condition>
  <arm_group>
    <arm_group_label>Methylphenidate transdermal system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MTS Patch 27.5mg, 41.3mg, 55mg, and 82.5mg for 7 Weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate Transdermal System</intervention_name>
    <description>MTS Patch 27.5mg, 41.3mg, 55mg, and 82.5mg for 7 Weeks</description>
    <arm_group_label>Methylphenidate transdermal system</arm_group_label>
    <other_name>MTS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must have participated in and completed SPD485-201 or participated in and
             completed a minimum of five of the seven weeks of double-blind treatment in study
             SPD485-302. Subjects who are participating in N17-021 may enroll in this study
             following completion of the End of Study/Termination visit procedures.

          -  Females of childbearing potential must have a negative urine pregnancy test at
             Baseline and must abstain from sexual activity that could result in pregnancy, or use
             acceptable contraceptives.

        Exclusion Criteria:

          -  Subject was terminated from SPD485-102, SPD495-201, SPD485-302 OR N17-021 for
             non-compliance or experienced a serious adverse event resulting in termination from
             the antecedent protocols

          -  Female subject is pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Findling RL, Wigal SB, Bukstein OG, Boellner SW, Abikoff HB, Turnbow JM, Civil R. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. Clin Ther. 2009 Aug;31(8):1844-55. doi: 10.1016/j.clinthera.2009.08.002.</citation>
    <PMID>19808143</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

